SAN DIEGO, May 24, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) has applied to OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
"Our management team believes that having the Company's shares trade over the OTCQB will enhance Regen's ability to complete future non toxic financings on terms favorable to the Company as we continue to move forward with our research and strategic alliances" noted Regen's Chairman & CEO David Koos.
Regen BioPharma Inc. has cleared an investigational new drug application (IND) with the U. S. Food and Drug Administration (FDA) and is preparing to enter Clinical Phase I in the treatment for aplastic anemia.
Additionally, the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer and has filed two subsequent investigational drug applications (INDs) with the U. S. Food and Drug Administration.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTCPINK: RGBP) and (OTC PINK: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
The Dorsee Company
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
SOURCE Regen BioPharma Inc.